Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06014905 · ClinicalTrials.gov registry record · Phase 1
Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma
A Phase 1 study of Meningioma, sponsored by Javier Villaneuva-Meyer, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT06014905 is a Phase 1 study of Meningioma that is actively recruiting participants, run by Javier Villaneuva-Meyer, MD. The registered enrollment target is 50 participants, below the 97-participant average among 21 other Meningioma trials with a reported enrollment target (48% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06014905, a Phase 1 study of Meningioma, is actively recruiting participants, sponsored by Javier Villaneuva-Meyer, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that includes the acquisition of magnetic resonance (MR) data performed on participants with meningioma to evaluate metabolism and aid in the non-invasive characterization of aggressive tumor behavior
Conditions Studied
Interventions
- OTHER Saline
- PROCEDURE Magnetic Resonance Image (MRI)
- DRUG Hyperpolarized carbon C 13 pyruvate
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-09-01 |
| Est. Completion | 2026-09-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06014905
The ClinicalTrials.gov registry entry for NCT06014905 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 97-participant average among 21 other Meningioma trials with a reported enrollment target (48% lower). The listed sponsor is Javier Villaneuva-Meyer, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Meningioma appearing as the primary indexed condition, and to 3 interventions - of which Saline is the first listed.
NCT06014905 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT06014905 about?
NCT06014905 is a clinical study titled "Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma". This is a Pilot/Phase I clinical study of hyperpolarized 13C (HP 13C) pyruvate injection that includes the acquisition of magnetic resonance (MR) data performed on participants with meningioma to evaluate metabolism and aid in the non-invasive characterization of aggressive tumor behavior
What is the current status of trial NCT06014905?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-09-01. Estimated completion is 2026-09-30.
What conditions does trial NCT06014905 study?
This clinical trial studies the following conditions: Meningioma.
What interventions are being tested in trial NCT06014905?
The interventions under investigation include: Saline (OTHER), Magnetic Resonance Image (MRI) (PROCEDURE), Hyperpolarized carbon C 13 pyruvate (DRUG).
Who is sponsoring clinical trial NCT06014905?
This trial is sponsored by Javier Villaneuva-Meyer, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06014905 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meningioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
RECRUITING · Phase 1
-
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
RECRUITING · Phase 1
-
Gallium Ga 68-DOTATATE PET/CT in Predicting Tumor Growth in Patients With Meningiomas
COMPLETED · Phase 1
-
Abemaciclib in Newly Diagnosed Meningioma Patients
RECRUITING · Phase 2
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.